You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
| Title |
Reporting quality of abstracts in phase III clinical trials of systemic therapy in metastatic solid malignancies
|
|---|---|
| Published in |
Trials, August 2015
|
| DOI | 10.1186/s13063-015-0885-9 |
| Pubmed ID | |
| Authors |
Shanthi Sivendran, Kristina Newport, Michael Horst, Adam Albert, Matthew D. Galsky |
| Abstract |
Manuscript abstracts represent a critical source of information for oncology practitioners. Practitioners may utilize the information contained in abstracts as a basis for treatment decisions particularly when full-text articles are not accessible. In 2007, the Consolidated Standards of Reporting Trials (CONSORT) extension statement for abstracts provided a minimum list of elements that should be included in abstracts. In this study we evaluate the degree of adherence to these recommendations and accessibility of full text publications in oncology publications. A systematic review of abstracts of randomized, controlled, phase III trials in metastatic solid malignancies published between January 2009 and December 2011 in PubMed, Medline, and Embase was completed. Abstracts were assigned a completeness score of 0-18 based on the number of CONSORT-recommended elements. Accessibility through open access was recorded. 174 abstracts with data for 95,956 patients were reviewed. The median completeness score was 9 (range, 3-17). Open access to full text articles was available for 80 % of abstracts. The remaining 20 % (35 out of 174) had a median cost of 38 USD (range: $22-49.95). The least frequently reported elements were: trial design description (20 %), participant allocation method (13 %), blinding (24 %), trial enrollment status (22 %), registration and name of trial (26 %) and funding source (18 %). The most frequently reported elements were eligibility criteria (98 %), study interventions (100 %), and primary endpoint (87 %). There is poor adherence to the CONSORT recommendations for abstract reporting in publications of randomized cancer clinical trials which could negatively impact clinical decision-making. Full-text articles are frequently available through open access. |
X Demographics
The data shown below were collected from the profiles of 16 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 3 | 19% |
| United States | 2 | 13% |
| Argentina | 1 | 6% |
| Canada | 1 | 6% |
| Unknown | 9 | 56% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 12 | 75% |
| Practitioners (doctors, other healthcare professionals) | 3 | 19% |
| Scientists | 1 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 37 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 4 | 11% |
| Professor > Associate Professor | 4 | 11% |
| Other | 3 | 8% |
| Lecturer | 3 | 8% |
| Student > Postgraduate | 3 | 8% |
| Other | 14 | 38% |
| Unknown | 6 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 43% |
| Social Sciences | 3 | 8% |
| Nursing and Health Professions | 2 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
| Computer Science | 1 | 3% |
| Other | 5 | 14% |
| Unknown | 9 | 24% |